- Report
- October 2024
- 100 Pages
Global
From €5704EUR$5,950USD£4,766GBP
- Report
- April 2025
- 269 Pages
Global
From €5225EUR$5,450USD£4,366GBP
- Report
- August 2024
- 175 Pages
Global
From €4793EUR$5,000USD£4,005GBP
- Report
- May 2024
- 136 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- May 2024
- 132 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- May 2024
- 134 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- December 2023
- 116 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- April 2023
- 160 Pages
Global
From €4744EUR$4,949USD£3,964GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €479EUR$500USD£401GBP
Amitiza is a prescription medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is a chloride channel activator that works by increasing fluid secretion in the intestines, which helps to soften stools and increase bowel movements. It is available in 8 mcg and 24 mcg capsules. Amitiza is the only FDA-approved medication for CIC and IBS-C that works by increasing fluid secretion in the intestines.
The Amitiza market is a subset of the larger gastrointestinal drugs market. It is composed of medications used to treat a variety of gastrointestinal conditions, including CIC and IBS-C. These medications are typically prescribed by gastroenterologists and other healthcare professionals.
Some companies in the Amitiza market include Allergan, Ironwood Pharmaceuticals, and Takeda Pharmaceuticals. Show Less Read more